ActiveSight to Provide Protein Crystallography to Ambit
News Nov 02, 2005
ActiveSight and Ambit Biosciences have that they have entered into a protein crystallography services agreement to advance Ambit's drug discovery program. The agreement covers the co-crystallization of Ambit proprietary molecules with proteins expressed by ActiveSight.
"We are delighted to provide Ambit, demonstrated leaders in the kinase arena, with structural biology support," stated Ronald V. Swanson, Ph.D., Chief Scientific Officer for ActiveSight.
"I am very pleased that we have initiated this technology collaboration in structural biology with ActiveSight," said Shripad Bhagwat, Sr. Vice President of Drug Discovery at Ambit. "This agreement is intended to accelerate Ambit's kinase drug discovery programs through the application of ActiveSight's protein crystallography technology applied across our discovery portfolio."
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE
BioAscent Secures Investment to Expand its Integrated Drug Discovery ServicesNews
£1.6m investment recognises BioAscent’s unique capabilities.READ MORE